1.Acknowledgment to Peer Reviewers in 2015: Real Scientific Contribution and Collaboration.
Journal of Korean Medical Science 2016;31(2):153-158
No abstract available.
2.Acknowledgment to Peer Reviewers in 2015: Real Scientific Contribution and Collaboration.
Journal of Korean Medical Science 2016;31(2):153-158
No abstract available.
3.Status of Parasitic Infections in Korea.
Journal of the Korean Medical Association 1998;41(7):737-745
No abstract available.
Korea*
4.Appreciations to Peer Reviewers in 2016: Contributions for the Scientific Community.
Journal of Korean Medical Science 2017;32(2):166-172
No abstract available.
Peer Review*
5.The Journal of Korean Medical Science as a Member of the International Committee of Medical Journal Editors.
Journal of Korean Medical Science 2017;32(2):165-165
No abstract available.
6.Launching a New Section 'Biomedical Engineering'.
Journal of Korean Medical Science 2016;31(10):1507-1507
No abstract available.
7.Management of Prostate Disorder in Aging Male.
Journal of the Korean Medical Association 1998;41(9):915-927
8.Peer Review in 2014: More Supports than Neglects.
Journal of Korean Medical Science 2015;30(1):120-125
No abstract available.
9.Difference between Duplicate and Secondary Publications.
Korean Journal of Aerospace and Environmental Medicine 2005;15(3):83-84
No abstract available.
10.Radioiodine Therapy For Differentiatd Thyroid Cancer.
Korean Journal of Nuclear Medicine 2000;34(4):265-275
The thyroid gland is an interesting endocrine organ where a spectrum of tumors with different behavior arise. At one end of spectrum there is differentiated thyroid carcinoma (DTC) with excellent prognosis, whereas at the other end of the spectrum is anaplastic thyroid cancer which has universally poor outcome. Radioiodine (I-131) therapy has been in use for the treatment of thyroid diseases since 1946. It was introduced by Seidlin et al. 1) Although the use of I-131 has been vouge for a long time, its use in therapy for well differentiated thyroid cancer is still controversial 2). This is because, thyroid cancers (TC) are generally slow growing tumors, with low mortality and normal spans of survival. To record recurrence and mortality, long term follow up studies over a period of two to three decades are needed to establish definite conclusions on the acceptable mode of treatment. The incidence of the disease being very low a large number of cases needed to establish a meaningful statistical data is lacking as most published reports deal with small series. Here again in the problem encountered are the differing protocols for treatment with I-131, the indications for treatment which may include or exclude ablation of residual thyroid tissue, cervical nodal and distal metastases. The dosage of I-131 used for ablation of residual thyroid tissue and metastatic disease also vary. The most reliable conclusion regarding I-131 treatment are obtained from studies reported on a large series of patients followed over a period of 2 decades or more from a single institute with a more or less unchanged protocol of management.
Follow-Up Studies
;
Humans
;
Incidence
;
Mortality
;
Neoplasm Metastasis
;
Prognosis
;
Recurrence
;
Thyroid Diseases
;
Thyroid Gland*
;
Thyroid Neoplasms*
Result Analysis
Print
Save
E-mail